What is CRMD's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.44B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CRMD?

P/E (TTM) is 2.37 and 52-week range is $5.63 to $13.02 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CRMD figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CRMD?

The company profile lists revenue (TTM) near $390M, net income (TTM) near $158M, EPS (TTM) near $2.10 when available from the market-data feed. Figures are informational and may lag live markets.

Where is CorMedix Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in Berkeley Heights, New Jersey, US, 77.9M shares outstanding, ISIN US21900C3088 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

CorMedix Inc.

$CRMD

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company is headquartered in Berkeley Heights, New Jersey and currently employs 191 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The firm is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The firm is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

Employees

191

Website

cormedix.com/

IPO

2010-03-25

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US21900C3088

Headquarters

Berkeley Heights, New Jersey, US

Shares outstanding

77.9M

NAICS sector

Manufacturing

Institutional ownership

58.07%

Browse other companiesFree AI scores and summaries for more stocks